Barely Significant
← all excerpts

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.

Vasc Health Risk Manag · 2014 · PMC4027919 · PMID 24868164

Europe PMCDOI
1
hedged sentence
0.1000
closest p · 2.0× alpha
0.1000
boldest claim

The sentences

did not reach statistical significanceP =0.10so close (0.05 < p ≤ 0.1)
The rate of the primary efficacy endpoint of death, MI, stroke, or severe recurrent ischemia requiring revascularization during 6 months was lower in the rivaroxaban group than in the placebo group (5.6 versus 7.0), but this difference did not reach statistical significance ( P =0.10). 28 ATLAS ACS 2 TIMI 51 trial Based on the Phase II study results, this Phase III study 29 investigated the potential of low doses of rivaroxaban plus antiplatelet therapy to improve cardiovascular outcomes in patients with recent ACS.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.